Akash Tewari
Stock Analyst at Jefferies
(1.62)
# 3,273
Out of 4,944 analysts
57
Total ratings
33.33%
Success rate
-1.39%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $7.09 | +41.04% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $47.85 | +42.11% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $58.30 | +62.95% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $112.78 | +33.00% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.42 | +367.84% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $131.62 | +43.60% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $26.58 | +200.98% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $43.10 | +74.01% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $660.49 | +53.67% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $28.63 | +74.64% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $37.36 | +100.75% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $17.40 | +78.16% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $561.55 | +66.86% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.16 | +55.01% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $7.60 | +136.84% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $646.60 | -20.66% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.49 | +177.35% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $82.71 | +51.13% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $13.94 | -21.09% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.31 | +1,197.71% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $36.88 | +103.36% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $373.46 | -59.57% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $38.49 | -27.25% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $7.09
Upside: +41.04%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $47.85
Upside: +42.11%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $58.30
Upside: +62.95%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $112.78
Upside: +33.00%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.42
Upside: +367.84%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $131.62
Upside: +43.60%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $26.58
Upside: +200.98%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $43.10
Upside: +74.01%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $660.49
Upside: +53.67%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $28.63
Upside: +74.64%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $37.36
Upside: +100.75%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $17.40
Upside: +78.16%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $561.55
Upside: +66.86%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.16
Upside: +55.01%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $7.60
Upside: +136.84%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $646.60
Upside: -20.66%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $6.49
Upside: +177.35%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $82.71
Upside: +51.13%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $13.94
Upside: -21.09%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.31
Upside: +1,197.71%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $36.88
Upside: +103.36%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $373.46
Upside: -59.57%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $38.49
Upside: -27.25%